Literature DB >> 7188437

Corticosteroid responsive pulmonary hypertension in systemic lupus erythematosus.

A Pines, N Kaplinsky, E Goldhammer, D Olchovsky, O Frankl.   

Abstract

Primary pulmonary hypertension is an irreversible and fatal disorder. Every effort should therefore be made to discover all the other treatable diseases which may be associated with pulmonary hypertension. The association of systemic lupus erythematosus and pulmonary hypertension was rarely reported in the past. We add another case in which pulmonary hypertension was the presenting symptom of systemic lupus erythematosus (SLE). In contrast to the previously reported cases, our patient responded well to corticosteroids. It is assumed that this favorable response was due to the relatively early stage of the disease, when the histopathologic pulmonary changes were still in the reversible inflammatory stage.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7188437     DOI: 10.1007/bf02032091

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  13 in total

1.  Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 4-1973.

Authors: 
Journal:  N Engl J Med       Date:  1973-01-25       Impact factor: 91.245

2.  Diazoxide in primary pulmonary hypertension.

Authors:  W P Klinke; J A Gilbert
Journal:  N Engl J Med       Date:  1980-01-10       Impact factor: 91.245

3.  Hope in primary pulmonary hypertension.

Authors:  J T Reeves
Journal:  N Engl J Med       Date:  1980-01-10       Impact factor: 91.245

4.  Treatment for primary pulmonary hypertension.

Authors:  W P Klinke
Journal:  Am Heart J       Date:  1980-10       Impact factor: 4.749

5.  Pulmonary vascular disease in systemic lupus erythematosus.

Authors:  A O Fayemi
Journal:  Am J Clin Pathol       Date:  1976-03       Impact factor: 2.493

6.  Primary pulmonary hypertension. Responses to indomethacin, terbutaline, and isoproterenol.

Authors:  B Person; R J Proctor
Journal:  Chest       Date:  1979-11       Impact factor: 9.410

7.  Oral hydralazine therapy for primary pulmonary hypertension.

Authors:  L J Rubin; R H Peter
Journal:  N Engl J Med       Date:  1980-01-10       Impact factor: 91.245

8.  Pulmonary hypertension and systemic lupus erythematosus.

Authors:  S S Nair; A D Askari; C G Popelka; J F Kleinerman
Journal:  Arch Intern Med       Date:  1980-01

9.  Primary pulmonary hypertension: effects of nifedipine.

Authors:  F Camerini; E Alberti; S Klugmann; A Salvi
Journal:  Br Heart J       Date:  1980-09

Review 10.  Pulmonary hypertension in systemic lupus erythematosus: report of four cases and review of the literature.

Authors:  H D Perez; N Kramer
Journal:  Semin Arthritis Rheum       Date:  1981-08       Impact factor: 5.532

View more
  1 in total

1.  Clinical aspects of pulmonary hypertension in patients with systemic lupus erythematosus and in patients with idiopathic pulmonary arterial hypertension.

Authors:  Son-Mi Chung; Chang-Keun Lee; Eun Young Lee; Bin Yoo; Sang-Do Lee; Hee-Bom Moon
Journal:  Clin Rheumatol       Date:  2006-02-22       Impact factor: 2.980

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.